OSRX Teams Up with Pro Rodeo Standout Sam Petersen Following Breakout 2025 Season
OSRX, Inc., an FDA-registered outsourcing facility specializing in compounded ophthalmic medications, today announced a partnership with professional rodeo athlete and Montana native Sam Petersen—the 2025 world No. 2 bareback rider and Wrangler National Finals Rodeo average champion. The collaboration advances the company’s Ride with OSRX campaign—an initiative celebrating rising American talent forged through discipline, resilience, and a relentless pursuit of excellence.
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
OSRX, Inc., a leading provider of compounded ophthalmic medications, announced that the company remains fully licensed, fully operational and continues to serve the needs of California ophthalmologists and optometrists, following a significant market shift involving a major competitor.
OSRX, Inc. Responds to Jury Verdict in Trademark Infringement Case
OSRX, Inc. today expressed its profound disappointment with the recent jury verdict in the case of ImprimisRx, LLC v. OSRX, Inc. The company believes the decision to be unjust and not based on the facts presented during the trial. Despite this setback, OSRX remains resolute in its commitment to challenge this outcome and address the significant issues that persist.
